As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.
This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.
Medications to manage care of bronchiectasis and NTM patients are often delivered via a nebulizer. This study compares a number of different OPEP/Nebulizer combinations using salbutamol as the modelled medication.
Medications to manage care of bronchiectasis and NTM patients are often delivered via a nebulizer. This study compares a number of different OPEP/Nebulizer combinations using salbutamol as the modelled medication.
May 1, 2018: Today is the 20th annual World Asthma Day, an event held each May to raise awareness of Asthma worldwide. World Asthma Day is organized by the Global Initiative for Asthma, or GINA (www.ginasthma.org), a World Health Organization collaborative and 501(c)3 organization founded in 1993.
If you suffer from Chronic Obstructive Lung Disease (COPD), simple tasks can start to feel larger than life. While there is no cure, there are steps you can take to improve your health and quality of life.
It is our pleasure to announce that in honour of the late Mitchell Baran, the founder and leader of the Trudell Medical Group of Companies, the City of London has renamed the portion of Third Street that two of the Trudell Companies are located to “Baransway Drive”.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
This laboratory and clinical overview demonstrates appreciable differences in pressure pulse waveforms for differing OPEP devices and then links these for the leading laboratory performing device into reported airway physiological changes and improved clinical outcomes.
The most efficient and effective delivery method remains that recommended in the device IFU (one actuation inhaled at a time, as well inhalation as soon as possible after actuation)
However, this laboratory-based study has indicated that a modified common-canister protocol with an anti-static VHC as the aerosol transfer vehicle has the potential to be a viable ‘off-label’ proposition in hospital situations where there is an urgent need to conserve pMDI medication as well as avoid cross-contamination from pathogenic viruses or bacteria
The widely differing inspiratory flow profiles from Turbuhaler† DPI contributed to greater variability in delivered dose to the carina.
MDI delivery via the AeroChamber Plus* Flow-Vu* VHC resulted in significantly increased mass to the carinal region irrespective of inhalation maneuver as well as reduced oropharyngeal deposited mass which in vivo is likely to result in reduced throat irritation or thrush in the mouth and throat.
The first day of school is less than a month away! This can be a busy and exciting time for you and your children. However, if your child suffers from asthma it is also a good time to take steps to protect them from the “September Spike”.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
Accelerate and scale your digital Metered Dose Inhaler (MDI) portfolio programs with the trusted Top Mounted Actuation Indicator (TMAI) technology platform.
From a UK perspective, BUD/F delivered via an MDI + VHC offers an economic benefit for the treatment of patients with mild asthma. Further analysis is required to determine if there would be any quality-adjusted life-year (QALY) effects based on the chosen intervention.
COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
